Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.6627 +0.0285 (+4.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,372,902
Open 0.6400
Bid (Size) 0.6620 (8,600)
Ask (Size) 0.6634 (1,200)
Prev. Close 0.6342
Today's Range 0.6400 - 0.6808
52wk Range 0.6230 - 5.140
Shares Outstanding 9,362,444
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN
From The Rosen Law Firm PA
Via GlobeNewswire

Performance

YTD
-2.4%
-2.4%
1 Month
-11.4%
-11.4%
3 Month
-83.8%
-83.8%
6 Month
-75.7%
-75.7%
1 Year
-78.0%
-78.0%

More News

Read More
News headline image
VTGN Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Vistagen Therapeutics, Inc. Securities Class Action Lawsuit
From Robbins LLP
Via GlobeNewswire
Why Did Vistagen Stock Tank 82% Today? ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 13, 2025 ↗
Via Benzinga
News headline image
VISTAGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action
From Robbins LLP
Via Business Wire
News headline image
These stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
On Friday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
On Thursday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
News headline image
Vistagen Appoints Nick Tressler as Chief Financial Officer
From Vistagen
Via Business Wire
News headline image
Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting
From Vistagen
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Vistagen (VTGN) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
News headline image
Examining the Future: VistaGen Therapeutics's Earnings Outlook ↗
Via Benzinga
News headline image
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
From Vistagen
Via Business Wire
News headline image
Vistagen to Participate in Stifel Healthcare Conference 2025
From Vistagen
Via Business Wire
News headline image
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
News headline image
Vistagen Appoints Paul Edick to its Board of Directors
From Vistagen
Via Business Wire

Frequently Asked Questions

Is Vistagen Therapeutics, Inc. - Common Stock publicly traded?
Yes, Vistagen Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Vistagen Therapeutics, Inc. - Common Stock trade on?
Vistagen Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vistagen Therapeutics, Inc. - Common Stock?
The ticker symbol for Vistagen Therapeutics, Inc. - Common Stock is VTGN on the Nasdaq Stock Market
What is the current price of Vistagen Therapeutics, Inc. - Common Stock?
The current price of Vistagen Therapeutics, Inc. - Common Stock is 0.6627
When was Vistagen Therapeutics, Inc. - Common Stock last traded?
The last trade of Vistagen Therapeutics, Inc. - Common Stock was at 01/22/26 04:00 PM ET
What is the market capitalization of Vistagen Therapeutics, Inc. - Common Stock?
The market capitalization of Vistagen Therapeutics, Inc. - Common Stock is 6.20M
How many shares of Vistagen Therapeutics, Inc. - Common Stock are outstanding?
Vistagen Therapeutics, Inc. - Common Stock has 6M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.